Pharma BD Deal Intelligence
A newly announced (June 2026) preclinical collaboration, option and license deal—too early to call win or bust. Jazz Pharmaceuticals paid AbCellera just $56 million upfront against up to $792 million in option fees and milestones to access T-cell engaging multispecific antibodies for gastrointestinal and other solid tumors, with no clinical data yet to validate the platform.
Option-based TCE antibody discovery deal in GI/solid tumors
Full analysis, sources & comparables →On June 17, 2026, Jazz Pharmaceuticals and AbCellera announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies for multiple gastrointestinal cancers and other solid tumors. AbCellera receives $56 million upfront and is eligible for up to $792 million in option fees and milestones for each program Jazz options, plus royalties. The collaboration initially covers two research programs, with a third to start within 12 months and up to two additional programs possible. Jazz holds the exclusive option to develop and commercialize resulting antibodies.
The collaboration targets multiple gastrointestinal cancers and other solid tumors with next-generation T-cell engaging (TCE) multispecific antibodies built on AbCellera's discovery engine, proprietary CD3-binding antibodies, costimulatory-targeting arms and multispecific protein-engineering technologies. Programs are preclinical; Jazz holds development/commercialization options.
Jazz and AbCellera launch a TCE multispecific-antibody discovery collaboration for GI/solid tumors; $56M upfront + up to $792M option fees/milestones per optioned program + royalties.
Modest committed upfront ($56M); the bulk of value is option/milestone-weighted and contingent on Jazz exercising options and clinical advancement.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Jazz Pharmaceuticals PLC / AbCellera Biologics Inc. (this deal) | 2026 | $848M | 50 |
| Jazz Pharmaceuticals PLC / GW Pharmaceuticals | 2021 | $7.2B | 77 |
| Jazz Pharmaceuticals PLC / Celator Pharmaceuticals | 2016 | $1.5B | 73 |
| Jazz Pharmaceuticals PLC / Actio Biosciences, Inc. | 2026 | $1.3B | — |
| Jazz Pharmaceuticals PLC / Chimerix, Inc. | 2025 | $935M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
← Browse all deals · How we score deals
More: 2026 deals · Jazz Pharmaceuticals PLC deals · Oncology deals